Newsletter | November 16, 2026

11.16.26 -- Rethinking The Inputs Behind Scalable T-Cell Therapy

Comparing Activation Methods For Gamma Delta T Cells

See how two activation methods compare for clinical-scale gamma delta T cell production. Anti-CD3/anti-CD28 co-activation addresses a common manufacturing hurdle and improves lentiviral transduction efficiency, supporting scalable gamma delta T cell therapy.

 

A Chemically Defined Medium For Cross-Platform T-Cell Expansion

TheraPEAK® T-VIVO® Cell Culture Medium uses only recombinant proteins, with no animal-derived components, to simplify CAR-T manufacturing. In testing, it supported stronger T-cell expansion than other commercially available media.

 

Human-Expressed Cytokines For Ex Vivo Cell Culture

TheraPEAK® AmpliCell® Cytokines are lyophilized, animal-component-free, xeno-free recombinant proteins produced in human cell lines. That expression gives them the post-translational modifications characteristic of native human cytokines for ex vivo cell culture.

 

Non-Viral Delivery For CRISPR Knock-In And Knock-Out

Efficient, scalable delivery of CRISPR/Cas9 is critical for gene and cell therapies, and electroporation leads non-viral clinical approaches. See how the 4D-Nucleofector™ LV Unit PRO enables robust, scalable T-cell gene editing.

 

SOLUTIONS

TheraPEAK® ActiCell® T Cell Activation Reagent

A biodegradable, nanoparticle-based CD3/CD28 agonist activates T cells with less stress than bead formats. It supports expansion of PBMCs or enriched T cells over 7 to 14 days in serum-free conditions.

 

Cell & Gene Therapy Product Portfolio

Accelerate your cell and gene therapy journey with integrated technologies, GMP expertise, and end-to-end solutions, from development through manufacturing, designed to help bring transformative therapies to patients faster.